RG
VIR icon

Rathbones Group’s Vir Biotechnology VIR Stock Holding History

Rathbones Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Hold
28,611
– – ﹤0.01% 542
2025
Q4 		$173K Hold
28,611
– – ﹤0.01% 588
2025
Q3 		$163K Hold
28,611
– – ﹤0.01% 591
2025
Q2 		$144K Hold
28,611
– – ﹤0.01% 573
2025
Q1 		$185K Hold
28,611
– – ﹤0.01% 535
2024
Q4 		$210K Hold
28,611
– – ﹤0.01% 529
2024
Q3 		$214K Hold
28,611
– – ﹤0.01% 535
2024
Q2 		$255K Sell
28,611
-3,456
-11% -$33.1K ﹤0.01% 516
2024
Q1 		$325K Hold
32,067
– – ﹤0.01% 474
2023
Q4 		$323K Buy
32,067
+10,000
+45% +$91.4K ﹤0.01% 464
2023
Q3 		$207K Buy
22,067
+11,000
+99% +$157K ﹤0.01% 534
2023
Q2 		$271K Hold
11,067
– – ﹤0.01% 344
2023
Q1 		$258K Hold
11,067
– – ﹤0.01% 354
2022
Q4 		$280K Hold
11,067
– – ﹤0.01% 345
2022
Q3 		$213K Hold
11,067
– – ﹤0.01% 367
2022
Q2 		$282K Hold
11,067
– – ﹤0.01% 355
2022
Q1 		$285K Hold
11,067
– – ﹤0.01% 365
2021
Q4 		$463K Buy
11,067
+6,067
+121% +$238K ﹤0.01% 321
2021
Q3 		$218K Buy
+5,000
New +$216K ﹤0.01% 385

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Rathbones Group's VIR Position: Q1 2026 in Review

Rathbones Group held its Vir Biotechnology (VIR) position steady in Q1 2026 at 28,611 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #542.

Rathbones Group first reported a position in VIR in Q3 2021 and has held it in 19 quarters since. The position peaked at $463K in Q4 2021. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Rathbones Group held 28,611 shares of Vir Biotechnology worth $256K as of Q1 2026.
  • Rathbones Group left its Vir Biotechnology share count unchanged in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #542 holding.
  • Rathbones Group first reported a position in Vir Biotechnology in Q3 2021 and has held it in 19 quarters since.
  • Rathbones Group's Vir Biotechnology position peaked at $463K in Q4 2021.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.